Invention Grant
- Patent Title: Human plasma kallikrein inhibitors
-
Application No.: US17526377Application Date: 2021-11-15
-
Publication No.: US11708332B2Publication Date: 2023-07-25
- Inventor: Pravin L. Kotian , Yarlagadda S. Babu , Minwan Wu , Venkat R. Chintareddy , V. Satish Kumar , Weihe Zhang
- Applicant: BioCryst Pharmaceuticals, Inc.
- Applicant Address: US NC Durham
- Assignee: BioCryst Pharmaceuticals, Inc.
- Current Assignee: BioCryst Pharmaceuticals, Inc.
- Current Assignee Address: US NC Durham
- Agency: Foley Hoag LLP
- Agent Dana M. Gordon; Laura A. Wzorek
- The original application number of the division: US16009943 2018.06.15
- Main IPC: C07D231/14
- IPC: C07D231/14 ; C07D403/12 ; C07D401/14 ; C07D401/04 ; C07D401/12 ; C07D403/04 ; C07D405/12 ; C07D413/04 ; C07D413/12 ; C07D417/12
Abstract:
Disclosed are compounds of formula I
as described herein, and pharmaceutically acceptable salts thereof. The compounds are disclosed to be inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.
as described herein, and pharmaceutically acceptable salts thereof. The compounds are disclosed to be inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.
Public/Granted literature
- US20230100082A1 HUMAN PLASMA KALLIKREIN INHIBITORS Public/Granted day:2023-03-30
Information query
